Several previous reports have shown that treatment of breast cancer cell lines with FGFR inhibitors downregulates CCND1 and CCND2 expression and inhibits CCND/CDK4 activity, resulting in decreased pRB phosphorylation [39,40]. The gene discussed is RB1; the disease is breast carcinoma.